newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

──FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter 2024 to Discuss the Design of a CM-101 Accelerated Approval Phase 3 Trial in Primary Sclerosing Cholangitis (PSC)── ──Cash Runway Extended to Early 2026;